Treatment and prognosis
There is no specific antiviral therapy approved for hantavirus pulmonary syndrome (HPS). Care is supportive and focused on aggressive ICU management of cardiogenic shock and non-cardiogenic pulmonary edema. Outcomes are dramatically better in centers with rapid access to ECMO. Andes virus case fatality remains 35-40% in well-resourced settings.
Supportive intensive care
The cornerstones are early ICU admission, careful fluid management (HPS patients are easily fluid-overloaded because of capillary leak), and lung-protective mechanical ventilation (low tidal volume, PEEP titration). Vasopressors — typically norepinephrine plus an inotrope such as dobutamine or epinephrine — are needed for cardiogenic shock. Pulmonary artery catheters or echocardiography help distinguish the low-output cardiogenic picture of HPS from septic shock and guide therapy.
Extracorporeal support
Veno-arterial ECMO has substantially improved outcomes for the sickest HPS patients. Chilean centers reported survival rates above 60% with early ECMO in ANDV cases that would otherwise have been fatal. The threshold for ECMO referral is low: refractory hypoxemia despite optimized ventilation, or refractory shock with a cardiac index below 2.0 L/min/m². Centers should arrange transfer to ECMO-capable facilities before the patient deteriorates to a point where transport is unsafe.
Antivirals and immunomodulation
Ribavirin reduces mortality in HFRS when started within the first four days, but trials in HPS have been negative or inconclusive. Favipiravir has in-vitro activity but lacks clinical evidence. Convalescent plasma and monoclonal antibodies are areas of active investigation; Argentine investigators reported encouraging results for high-titer convalescent plasma in early ANDV disease, though selection bias limits interpretation. Corticosteroids have not shown benefit and may worsen outcomes.
Mortality and prognosis
Case fatality is approximately 36% for Sin Nombre virus and 35-50% for Andes virus, depending on series and ICU resources. Predictors of death include shock at presentation, lactate above 4 mmol/L, hematocrit above 50%, and severe thrombocytopenia. Survivors typically recover lung and cardiac function but may have prolonged fatigue and reduced exercise tolerance. Long-term follow-up studies of ANDV survivors show measurable reductions in diffusion capacity persisting for up to a year, and a smaller subset have cognitive complaints.
What clinicians should NOT do
Avoid aggressive fluid resuscitation in a hypotensive HPS patient who is not clearly hypovolemic — this drives pulmonary edema. Avoid corticosteroids outside clinical trials. Do not delay ECMO referral while awaiting confirmatory PCR or serology; treat empirically based on clinical and laboratory picture.
- •No specific antiviral is approved — care is supportive ICU
- •Early ECMO referral substantially improves survival
- •Avoid aggressive fluid resuscitation — drives pulmonary edema
- •Ribavirin helps in HFRS but not in HPS
- •Survivors may have lung function and cognitive sequelae for months
FAQ
Is there a treatment that works?+
There is no curative antiviral. Survival depends on early recognition, ICU support and rapid escalation to ECMO when needed.
Should I take antibiotics?+
Antibiotics do not treat hantavirus, but they are often started empirically while ruling out bacterial pneumonia or sepsis. Once hantavirus is confirmed, antibiotics are stopped if no co-infection is identified.